Azithromycin + Azithromycin and amoxicillin + Placebo

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Postpartum Sepsis

Conditions

Postpartum Sepsis, Postpartum Endometritis, Postpartum Fever

Trial Timeline

Jan 12, 2018 → Oct 1, 2020

NCT ID

NCT03248297

About Azithromycin + Azithromycin and amoxicillin + Placebo

Azithromycin + Azithromycin and amoxicillin + Placebo is a approved stage product being developed by Merck for Postpartum Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT03248297. Target conditions include Postpartum Sepsis, Postpartum Endometritis, Postpartum Fever.

What happened to similar drugs?

2 of 9 similar drugs in Postpartum Sepsis were approved

Approved (2) Terminated (0) Active (7)

✅Eptacog alfa (NovoSeven)Novo NordiskApproved

✅ZULRESSO®Supernus PharmaceuticalsApproved

🔄Misoprostol + OxytocinCiplaPhase 3

🔄aripiprazoleBristol Myers SquibbPhase 3

🔄SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg CapsulesBiogenPhase 3

🔄SAGE-217 + PlaceboBiogenPhase 3

🔄LPCN 1154A + PlaceboLipocinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03248297	Approved	Completed	Jan 12, 2018	Oct 1, 2020	Postpartum Sepsis

Competing Products

20 competing products in Postpartum Sepsis

See all competitors

Product	Company	Stage	Hype Score
Misoprostol + Oxytocin	Cipla	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	27
Eptacog alfa (NovoSeven)	Novo Nordisk	Approved	50
Eptacog alfa (activated)	Novo Nordisk	Pre-clinical	26
aripiprazole	Bristol Myers Squibb	Phase 3	40
fibrinogen concentrate + Placebo	CSL	Phase 1/2	24
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules	Biogen	Phase 3	37
SAGE-217 + Placebo	Biogen	Phase 3	37
Zuranolone	Biogen	Pre-clinical	30
Zuranolone	Biogen	Pre-clinical	30
LPCN 1154A + Placebo	Lipocine	Phase 3	30
Goserelin 3.6 mg implant + Placebo	Brain Biotech	Pre-clinical	16
ZULRESSO (brexanolone) injection	Supernus Pharmaceuticals	Pre-clinical	20
Placebo + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
ZULRESSO®	Supernus Pharmaceuticals	Approved	37
SAGE-547	Supernus Pharmaceuticals	Phase 2	29
Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
SAGE-547 + Placebo	Supernus Pharmaceuticals	Phase 2	29
GH001	GH Research	Phase 2	21
Brexanolone	Brain Biotech	Pre-clinical	16